Skip to main content

News

June 15, 2020
Targeted chemo is feasible, safe, and may improve quality of life.
October 11, 2019
Areas ranging from immuno-oncology to artificial intelligence are poised to shape the future of care. The first day of the Symposium on Clinical Interventional Oncology featured a session focusing on emerging trends in interventional oncology. 
October 11, 2019
Friday, October 11, 2019 (Miami, FL) — The first day of the Symposium on Clinical Interventional Oncology (CIO) explored radioembolization using Y90 in detail.
October 10, 2019
Addressing the needs of physicians new to the interventional oncology (IO) field, the Symposium on Clinical Interventional Oncology (CIO) opened its first day with a pre-conference session focusing on IO fundamentals.
October 09, 2019
CGP Obtains a 12-Month Option to Offer to Acquire the Remaining Shares of OncoSec at the Greater of $4.50 Per Share or 110% of the Market Price
September 19, 2019
Leading the effort to connect the interventional oncology community, HMP, a leading health care event and education company, announced today the launch of the new IO Learning.
September 13, 2019
Torpedo™ Device Includes Pre-Shaped, Pre-Loaded Gelatin Foam, Removing Need for Manual Shaping and Loading
August 19, 2019
MARLBOROUGH, Mass., Aug. 19, 2019 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced the completion of its acquisition of BTG plc. (LSE: BTG) pursuant to the previously announced scheme of arrangement. BTG develops…
June 28, 2019
On May 10, 2019, the Food and Drug Administration approved ramucirumab (CYRAMZA®, Eli Lilly and Company) as a single agent for hepatocellular carcinoma (HCC) in patients who have an alpha fetoprotein (AFP) of ≥ 400 ng/mL and have been…
June 26, 2019
WOBURN, Mass. (June 20, 2019) –– Sirtex Medical, a leading manufacturer of targeted liver cancer therapies, today announced delivery of the 100,000th patient dose of SIR-Spheres® Y-90 resin microspheres, a treatment for patients with liver cancer.*…
June 11, 2019
Varian (NYSE: VAR) today announced it has acquired Austin, Texas-based Endocare and Hangzhou, China-based, Alicon, to expand its portfolio of multidisciplinary integrated cancer care solutions. Endocare is a leading provider of hardware and software…
Back to Top